BibTex RIS Cite

Dirençli meraljia parestetikaya pulsed radyofrekans, metilprednizolon ve pulsed radyofrekans+metilprednizolon nöromodülasyonunun klinik etkileri

Year 2018, Volume: 11 Issue: 1, 33 - 41, 01.01.2018

Abstract

GİRİŞ ve AMAÇ: Bu çalışmada ultrasonografi (USG) rehberliğinde lateral femoral kutanöz sinir (LFKS) nöromodülasyonu için farklı 3 yöntem olan P-RF, Metiprednizolon asetat+25 mg bupivakain ve P-RF+Metilprednizolon asetat+25 mg bupivakain in etkinlikleri ve birbirlerine üstünlükleri olup olmadığını göstermeyi amaçladıkYÖNTEM ve GEREÇLER: Biz tıbbi tedaviye dirençli MP sı olan P-RF (Grup PRF), Metiprdnizolon+25 mg bupivakain (Grup M) ve P-RF+Metilprednizolon+25 mg bupivakain (Grup PRF+M) ile nöromodülasyona maruz kalan 60 hastanın klinik bilgilerini sırasıyla gözden geçirdik. Pozitif cevaplı tanısal blok takibinde hastalara P-RF (10 dakika 42ºC de nöromodülasyon), Metilprednizolon (25 mg bupivakain içinde 40 mg metilprednizolon) ve P-RF+Metilprednizolon (10 dakika 42ºC de nöromodülasyon+25 mg bupivakain içinde 40 mg metilprednizolon) nöromodülasyon uygulandı. Hastaların ağrısı 10 cm visual analog scala (VAS) ile değerlendirildi. P-RF, Metilprednizolon ve P-RF+Metilprednizolon uygulanan MP lı hastaların VAS değerleri istatistiksel olarak değerlendirildi. BULGULAR: Hastaların başlangıçtaki medyan VAS değerleri Grup PRF 7.5(7-9), Grup M 7.5 (6-10) ve Grup PRF+M 7 (7-9). Bu değerler sırasıyla 1-3.ay ve 1.yılda Grup PRF 5 (4-8), Grup M 3 (2-8) ve Grup PRF+M 3 (2-7))-Grup PRF 5 (3-8), Grup M 3 (2-9) ve Grup PRF+M 3 (2-7)) ve Grup PRF 7 (4-9), Grup M 8 (3-9) ve Grup PRF+M 4 (2-7)) idi.TARTIŞMA ve SONUÇ: LFKS in P-RF+Metilprednizolonla+25 mg bupivakain nöromodülasyonu komplikasyonsuz ve önemli derecede, uzun dönem ağrı iğleşmesi sağlıyor. Bu nedenle LFKS in P-RF+Metilprednizolonla+25 mg bupivakain nöromodülasyonu konservatif tıbbi tedaviye dirençli MP lı hastalarda alternatif tedavi olarak kullanılabilir.

Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica

Year 2018, Volume: 11 Issue: 1, 33 - 41, 01.01.2018

Abstract

INTRODUCTION: In this study we aimed to compare the efficacy of three different methods (P-RF, Methylprednisolone+25 mg bupivacaine and P-RF+Methylprednisolone+25 mg bupivacaine) for USG guiding lateral femoral cutaneous nerve noromodulation and whether one is soperior to the other METHODS: We retrospectively reviewed the clinical data of 60 patients with medically intractable MP who underwent P-RF (Grup PRF), Methylprednisolone+25 mg bupivacaine (Grup M) and P-RF+Methylprednisolone+25 mg bupivacaine (Grup PRF+M) neuromodulation of the LFCN. Following a positive response to the diagnostic nerve block, patients underwent P-RF (neuromodulation at 42ºC for 10 minutes), Methylprednisolone (40mg in 25mg isobaric bupivacaine) and P-RF+Methylprednisolone (neuromodulation at 42ºC for 10 minutes+40mg in 25mg isobaric bupivacaine). Patient pain was evaluated using a 10 cm visual analog scale (VAS). In patientswith MP who received P-RF, Methylprednisolone+25 mg bupivacaine and P-RF+Methylprednisolone+25 mg bupivacaine, we statistically evaluated VAS scores and the presence of any complications for 1-3-6. months and 1. year after the procedure.RESULTS: The median initial patients VAS scores were Group PRF 7.5(7-9), Group M 7.5 (6-10) and Group PRF+M 7 (7-9). These scores were decreased to Group PRF 5 (4-8), Group M 3 (2-8) and Group PRF 3 (2-7))-Group PRF 5 (3-8), Group M 3 (2-9) and Group PRF+M 3 (2-7)) and Group PRF 7 (4-9), Group M 8 (3-9) and Group PRF+M 4 (2-7)) at the 1-3. month and 1. year follow-up, respectively. DISCUSSION AND CONCLUSION: P-RF+Methylprednisolone+25 mg bupivacaine neuromodulation of the LFCN provides immediate and long-lasting pain relief without complications. Therefore, P-RF+Methylprednisolone+25 mg bupivacaine of the LFCN can be used as an alternative treatment in patients with MP who are refractory to conservative medical treatment.

There are 0 citations in total.

Details

Other ID JA23ZG85YS
Journal Section Research Article
Authors

Abdulkadir Yektaş This is me

Bedih Balkan This is me

Publication Date January 1, 2018
Submission Date January 1, 2018
Published in Issue Year 2018 Volume: 11 Issue: 1

Cite

APA Yektaş, A., & Balkan, B. (2018). Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica. Pamukkale Medical Journal, 11(1), 33-41.
AMA Yektaş A, Balkan B. Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica. Pam Med J. January 2018;11(1):33-41.
Chicago Yektaş, Abdulkadir, and Bedih Balkan. “Clinical Efficacy of Pulsed Radiofrequency, Methylprednisolone and Pulsed radiofrequency+methylprednisolone Neuromodulation for Intractable Meralgia Paresthetica”. Pamukkale Medical Journal 11, no. 1 (January 2018): 33-41.
EndNote Yektaş A, Balkan B (January 1, 2018) Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica. Pamukkale Medical Journal 11 1 33–41.
IEEE A. Yektaş and B. Balkan, “Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica”, Pam Med J, vol. 11, no. 1, pp. 33–41, 2018.
ISNAD Yektaş, Abdulkadir - Balkan, Bedih. “Clinical Efficacy of Pulsed Radiofrequency, Methylprednisolone and Pulsed radiofrequency+methylprednisolone Neuromodulation for Intractable Meralgia Paresthetica”. Pamukkale Medical Journal 11/1 (January 2018), 33-41.
JAMA Yektaş A, Balkan B. Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica. Pam Med J. 2018;11:33–41.
MLA Yektaş, Abdulkadir and Bedih Balkan. “Clinical Efficacy of Pulsed Radiofrequency, Methylprednisolone and Pulsed radiofrequency+methylprednisolone Neuromodulation for Intractable Meralgia Paresthetica”. Pamukkale Medical Journal, vol. 11, no. 1, 2018, pp. 33-41.
Vancouver Yektaş A, Balkan B. Clinical efficacy of pulsed radiofrequency, methylprednisolone and pulsed radiofrequency+methylprednisolone neuromodulation for intractable meralgia paresthetica. Pam Med J. 2018;11(1):33-41.

Creative Commons Lisansı
Pamukkale Medical Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License